SpringWorks TherapeuticsSWTX
Market Cap: $2.88B
About: SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
Employees: 305
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
74% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 54
0% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]
2.24% less ownership
Funds ownership: 106.31% [Q1] → 104.07% (-2.24%) [Q2]
3% less funds holding
Funds holding: 213 [Q1] → 206 (-7) [Q2]
18% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 38
25% less capital invested
Capital invested by funds: $3.86B [Q1] → $2.91B (-$955M) [Q2]
86% less call options, than puts
Call options by funds: $1.59M | Put options by funds: $11.8M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
JP Morgan Anupam Rama 51% 1-year accuracy 30 / 59 met price target | 75%upside $68 | Overweight Maintained | 4 Sept 2024 |
HC Wainwright & Co. Robert Burns 40% 1-year accuracy 57 / 144 met price target | 96%upside $76 | Buy Reiterated | 28 Aug 2024 |
Financial journalist opinion
Based on 7 articles about SWTX published over the past 30 days